- Biogen Idec is a biotechnology company focused on neurology, immunology, oncology, hemophilia, and cardiopulmonary diseases. In 2010, it had total revenue of $4.71 billion and net income of $0.89 billion. - The company's key drugs include AVONEX and TYSABRI for treating multiple sclerosis and RITUXAN for treating non-Hodgkin's lymphoma and rheumatoid arthritis. - Biogen Idec's goals in 2007 of enrolling 100,000 patients on TYSABRI and deriving over 40% of revenue internationally have not yet been met.